Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theodoros Eleftheriadis

Showing results (1-10 of 210) with videos related to

Pageof 21
Sort By:
Frontiers in Immunology|August 29, 2018
What May Constrain the Success of Indoleamine 2,3-Dioxygenase 1 Inhibitors in Cancer Immunotherapy?Theodoros Eleftheriadis
Medical Hypotheses|November 11, 2011
The existence of two types of proteasome, the constitutive proteasome and the immunoproteasome, may serve as another layer of protection against autoimmunityTheodoros Eleftheriadis
International Journal of Molecular Sciences|April 12, 2022
Molecular Aspects of Renal Immunology: Current Status and Future PerspectivesTheodoros Eleftheriadis, Marta Crespo
Bio-Protocol|March 3, 2021
Assessment of Humoral Alloimmunity in Mixed Lymphocyte ReactionGeorgios Pissas, Theodoros Eleftheriadis
Inflammation & Allergy Drug Targets|July 16, 2009
Toll-like receptors and kidney diseasesTheodoros Eleftheriadis, Brian R Lawson
Seminars in Dialysis|May 3, 2019
Is oxidative stress an issue in peritoneal dialysis?Stefanos Roumeliotis, Theodoros Eleftheriadis, Vassilios Liakopoulos
Clinical Nutrition (Edinburgh, Scotland)|November 4, 2019
A cohort of fat enough but malnourished hemodialysis patientsTheodoros Eleftheriadis, Vassilios Liakopoulos, Ioannis Stefanidis
Hepatitis Monthly|September 26, 2012
Decreasing High Failure Rate of Vaccinations in Patients With Chronic Kidney Disease; not Just a Matter of QuantityTheodoros Eleftheriadis, Vassilios Liakopoulos, Ioannis Stefanidis
Kidney International|November 24, 2018
Screening for renal cell carcinoma in dialysis patientsVassilios Liakopoulos, Theodoros Eleftheriadis, Peter R Mertens
Kidney Medicine|May 11, 2022
Should We Use Dialyzable β-Blockers in Hemodialysis?Panagiotis I Georgianos, Theodoros Eleftheriadis, Vassilios Liakopoulos
Pageof 21

Showing results (1-10 of 210) with videos related to

Sort By:
Pageof 21
Frontiers in Immunology|August 29, 2018
What May Constrain the Success of Indoleamine 2,3-Dioxygenase 1 Inhibitors in Cancer Immunotherapy?Theodoros Eleftheriadis
Medical Hypotheses|November 11, 2011
The existence of two types of proteasome, the constitutive proteasome and the immunoproteasome, may serve as another layer of protection against autoimmunityTheodoros Eleftheriadis
International Journal of Molecular Sciences|April 12, 2022
Molecular Aspects of Renal Immunology: Current Status and Future PerspectivesTheodoros Eleftheriadis, Marta Crespo
Bio-Protocol|March 3, 2021
Assessment of Humoral Alloimmunity in Mixed Lymphocyte ReactionGeorgios Pissas, Theodoros Eleftheriadis
Inflammation & Allergy Drug Targets|July 16, 2009
Toll-like receptors and kidney diseasesTheodoros Eleftheriadis, Brian R Lawson
Seminars in Dialysis|May 3, 2019
Is oxidative stress an issue in peritoneal dialysis?Stefanos Roumeliotis, Theodoros Eleftheriadis, Vassilios Liakopoulos
Clinical Nutrition (Edinburgh, Scotland)|November 4, 2019
A cohort of fat enough but malnourished hemodialysis patientsTheodoros Eleftheriadis, Vassilios Liakopoulos, Ioannis Stefanidis
Hepatitis Monthly|September 26, 2012
Decreasing High Failure Rate of Vaccinations in Patients With Chronic Kidney Disease; not Just a Matter of QuantityTheodoros Eleftheriadis, Vassilios Liakopoulos, Ioannis Stefanidis
Kidney International|November 24, 2018
Screening for renal cell carcinoma in dialysis patientsVassilios Liakopoulos, Theodoros Eleftheriadis, Peter R Mertens
Kidney Medicine|May 11, 2022
Should We Use Dialyzable β-Blockers in Hemodialysis?Panagiotis I Georgianos, Theodoros Eleftheriadis, Vassilios Liakopoulos
Pageof 21